The treatment of EGFR and HER2 overexpressing gastric cancer cells with Afatinib (a pan-ErbB2 family TKI) and lapatinib (EGFR, ErbB2 inhibitor) reduced PD-L1 expression levels [72]. The gene discussed is ERBB2; the disease is gastric cancer.